Pulmonx (NASDAQ:LUNG – Get Free Report) and Titan Medical (NASDAQ:TMDIF – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.
Institutional & Insider Ownership
91.0% of Pulmonx shares are owned by institutional investors. Comparatively, 0.0% of Titan Medical shares are owned by institutional investors. 6.8% of Pulmonx shares are owned by company insiders. Comparatively, 0.0% of Titan Medical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Volatility and Risk
Pulmonx has a beta of 0.52, indicating that its stock price is 48% less volatile than the S&P 500. Comparatively, Titan Medical has a beta of 1.26, indicating that its stock price is 26% more volatile than the S&P 500.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Pulmonx | 0 | 3 | 5 | 0 | 2.63 |
| Titan Medical | 0 | 0 | 0 | 0 | 0.00 |
Pulmonx presently has a consensus price target of $11.53, indicating a potential upside of 339.89%. Given Pulmonx’s stronger consensus rating and higher possible upside, analysts clearly believe Pulmonx is more favorable than Titan Medical.
Profitability
This table compares Pulmonx and Titan Medical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Pulmonx | -65.27% | -63.69% | -34.94% |
| Titan Medical | N/A | -82.31% | -51.47% |
Valuation and Earnings
This table compares Pulmonx and Titan Medical”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Pulmonx | $83.79 million | 1.26 | -$56.39 million | ($1.44) | -1.82 |
| Titan Medical | $17.63 million | 1.67 | $6.95 million | $0.05 | 5.17 |
Titan Medical has lower revenue, but higher earnings than Pulmonx. Pulmonx is trading at a lower price-to-earnings ratio than Titan Medical, indicating that it is currently the more affordable of the two stocks.
Summary
Pulmonx beats Titan Medical on 8 of the 14 factors compared between the two stocks.
About Pulmonx
Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
About Titan Medical
Titan Medical Inc. operates as a medical technology company. It focuses on the development and licensing of robotic assisted surgical technologies. The company is headquartered in Toronto, Canada.
Receive News & Ratings for Pulmonx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmonx and related companies with MarketBeat.com's FREE daily email newsletter.
